Kimberly Nearing
Directeur/Membre du Conseil chez Ethismos Research, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Anthony A. McKinney | M | 62 |
Ethismos Research, Inc.
Ethismos Research, Inc. BiotechnologyHealth Technology Ethismos Research, Inc. is a clinical-stage drug development company located in an undisclosed location. Ethismos is developing pharmaceutical treatments for pain, depression, and substance use disorders. Amitifadine is different from opioids and addiction treatments because it is not believed to be addictive, nor is it a stimulant or an opioid. Ethismos plans to commence phase 2 amitifadine clinical trials for opioid-sparing and facilitation of opioid taper as a non-opioid analgesic in chronic pain patients treated with long-term opioids. The American company is also exploring amitifadine trials in depression maintenance post-ketamine treatment, methamphetamine dependence, and nicotine cessation. The private company was founded by Anthony A. McKinney and he has been the CEO since incorporation. The company is continuing the development of the patented small molecule, amitifadine, a triple reuptake inhibitor, originally developed by euthymics bioscience, and acquired by ethismos in 2017. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 1 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Kimberly Nearing
- Réseau Personnel